OGFR_HUMAN
ID OGFR_HUMAN Reviewed; 677 AA.
AC Q9NZT2; O96029; Q4VXW5; Q96CM2; Q9BQW1; Q9H4H0; Q9H7J5; Q9NZT3; Q9NZT4;
DT 01-FEB-2003, integrated into UniProtKB/Swiss-Prot.
DT 06-MAR-2007, sequence version 3.
DT 03-AUG-2022, entry version 177.
DE RecName: Full=Opioid growth factor receptor;
DE Short=OGFr;
DE AltName: Full=Protein 7-60;
DE AltName: Full=Zeta-type opioid receptor;
GN Name=OGFR;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND VARIANT THR-577.
RC TISSUE=Placenta;
RX PubMed=10677613; DOI=10.1016/s0006-8993(99)02330-6;
RA Zagon I.S., Verderame M.F., Allen S.S., McLaughlin P.J.;
RT "Cloning, sequencing, chromosomal location, and function of cDNAs encoding
RT an opioid growth factor receptor (OGFr) in humans.";
RL Brain Res. 856:75-83(2000).
RN [2]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT THR-577.
RA Takanosu M., Liu J., Mayne R., Wood B.M., Brewton R.G.;
RT "Genomic structure of human gene 7-60.";
RL Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN [3]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX PubMed=11780052; DOI=10.1038/414865a;
RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT "The DNA sequence and comparative analysis of human chromosome 20.";
RL Nature 414:865-871(2001).
RN [4]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC TISSUE=Skin;
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [5]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 37-677 (ISOFORM 1), AND VARIANT
RP THR-577.
RC TISSUE=Spleen;
RX PubMed=11214971; DOI=10.1093/dnares/7.6.357;
RA Hattori A., Okumura K., Nagase T., Kikuno R., Hirosawa M., Ohara O.;
RT "Characterization of long cDNA clones from human adult spleen.";
RL DNA Res. 7:357-366(2000).
RN [6]
RP REVIEW.
RX PubMed=11890982; DOI=10.1016/s0165-0173(01)00160-6;
RA Zagon I.S., Verderame M.F., McLaughlin P.J.;
RT "The biology of the opioid growth factor receptor (OGFr).";
RL Brain Res. Brain Res. Rev. 38:351-376(2002).
RN [7]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315, AND IDENTIFICATION BY
RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Cervix carcinoma;
RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT networks.";
RL Cell 127:635-648(2006).
RN [8]
RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Cervix carcinoma;
RX PubMed=16964243; DOI=10.1038/nbt1240;
RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT "A probability-based approach for high-throughput protein phosphorylation
RT analysis and site localization.";
RL Nat. Biotechnol. 24:1285-1292(2006).
RN [9]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-420, AND IDENTIFICATION BY
RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Embryonic kidney;
RX PubMed=17525332; DOI=10.1126/science.1140321;
RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA Gygi S.P., Elledge S.J.;
RT "ATM and ATR substrate analysis reveals extensive protein networks
RT responsive to DNA damage.";
RL Science 316:1160-1166(2007).
RN [10]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-484, AND IDENTIFICATION BY
RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Cervix carcinoma;
RX PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA Elledge S.J., Gygi S.P.;
RT "A quantitative atlas of mitotic phosphorylation.";
RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN [11]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-378, AND IDENTIFICATION BY
RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Liver;
RX PubMed=18318008; DOI=10.1002/pmic.200700884;
RA Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA Zou H., Gu J.;
RT "Large-scale phosphoproteome analysis of human liver tissue by enrichment
RT and fractionation of phosphopeptides with strong anion exchange
RT chromatography.";
RL Proteomics 8:1346-1361(2008).
RN [12]
RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP SPECTROMETRY [LARGE SCALE ANALYSIS].
RX PubMed=19413330; DOI=10.1021/ac9004309;
RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT refined SCX-based approach.";
RL Anal. Chem. 81:4493-4501(2009).
RN [13]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-378, AND IDENTIFICATION BY
RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA Mann M., Daub H.;
RT "Large-scale proteomics analysis of the human kinome.";
RL Mol. Cell. Proteomics 8:1751-1764(2009).
RN [14]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-378, AND IDENTIFICATION BY
RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Leukemic T-cell;
RX PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA Rodionov V., Han D.K.;
RT "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT reveals system-wide modulation of protein-protein interactions.";
RL Sci. Signal. 2:RA46-RA46(2009).
RN [15]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315; SER-361; SER-378;
RP SER-484; SER-537; SER-557 AND SER-617, AND IDENTIFICATION BY MASS
RP SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Cervix carcinoma;
RX PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT site occupancy during mitosis.";
RL Sci. Signal. 3:RA3-RA3(2010).
RN [16]
RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA Bennett K.L., Superti-Furga G., Colinge J.;
RT "Initial characterization of the human central proteome.";
RL BMC Syst. Biol. 5:17-17(2011).
RN [17]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315 AND SER-378, AND
RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT "System-wide temporal characterization of the proteome and phosphoproteome
RT of human embryonic stem cell differentiation.";
RL Sci. Signal. 4:RS3-RS3(2011).
RN [18]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-299; SER-315; SER-349;
RP SER-361; SER-378; SER-382; SER-403 AND SER-484, AND IDENTIFICATION BY MASS
RP SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Cervix carcinoma, and Erythroleukemia;
RX PubMed=23186163; DOI=10.1021/pr300630k;
RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA Mohammed S.;
RT "Toward a comprehensive characterization of a human cancer cell
RT phosphoproteome.";
RL J. Proteome Res. 12:260-271(2013).
RN [19]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315 AND SER-378, AND
RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Liver;
RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA Ye M., Zou H.;
RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT phosphoproteome.";
RL J. Proteomics 96:253-262(2014).
CC -!- FUNCTION: Receptor for opioid growth factor (OGF), also known as Met-
CC enkephalin. Seems to be involved in growth regulation.
CC -!- INTERACTION:
CC Q9NZT2; Q9NYB0: TERF2IP; NbExp=2; IntAct=EBI-1044212, EBI-750109;
CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus {ECO:0000250}.
CC Note=The OGF/OGFR complex is probably translocated to the nucleus.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Name=1;
CC IsoId=Q9NZT2-1; Sequence=Displayed;
CC Name=2;
CC IsoId=Q9NZT2-2; Sequence=VSP_004060;
CC -!- TISSUE SPECIFICITY: Highly expressed in the heart and liver, moderately
CC in skeletal muscle and kidney and to a lesser extent in brain and
CC pancreas. Expressed in fetal tissues including liver and kidney.
CC -!- SIMILARITY: Belongs to the opioid growth factor receptor family.
CC {ECO:0000305}.
CC -!- SEQUENCE CAUTION:
CC Sequence=AAD03737.1; Type=Frameshift; Evidence={ECO:0000305};
CC Sequence=AAD03745.1; Type=Frameshift; Evidence={ECO:0000305};
CC -!- WEB RESOURCE: Name=Wikipedia; Note=OGFr entry;
CC URL="https://en.wikipedia.org/wiki/OGFr";
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AF172451; AAF64404.1; -; mRNA.
DR EMBL; AF172452; AAF64405.1; -; mRNA.
DR EMBL; AF172453; AAF64406.1; -; mRNA.
DR EMBL; AF112980; AAD03745.1; ALT_FRAME; Genomic_DNA.
DR EMBL; AF109134; AAD03737.1; ALT_FRAME; mRNA.
DR EMBL; AL035669; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; BC014137; AAH14137.1; -; mRNA.
DR EMBL; AK024485; BAB15775.1; -; mRNA.
DR CCDS; CCDS13504.1; -. [Q9NZT2-1]
DR RefSeq; NP_031372.2; NM_007346.3. [Q9NZT2-1]
DR AlphaFoldDB; Q9NZT2; -.
DR BioGRID; 116239; 35.
DR IntAct; Q9NZT2; 7.
DR MINT; Q9NZT2; -.
DR STRING; 9606.ENSP00000290291; -.
DR ChEMBL; CHEMBL4105797; -.
DR GlyGen; Q9NZT2; 1 site, 1 O-linked glycan (1 site).
DR iPTMnet; Q9NZT2; -.
DR PhosphoSitePlus; Q9NZT2; -.
DR SwissPalm; Q9NZT2; -.
DR BioMuta; OGFR; -.
DR DMDM; 146331047; -.
DR EPD; Q9NZT2; -.
DR jPOST; Q9NZT2; -.
DR MassIVE; Q9NZT2; -.
DR MaxQB; Q9NZT2; -.
DR PaxDb; Q9NZT2; -.
DR PeptideAtlas; Q9NZT2; -.
DR PRIDE; Q9NZT2; -.
DR ProteomicsDB; 83507; -. [Q9NZT2-1]
DR ProteomicsDB; 83508; -. [Q9NZT2-2]
DR Antibodypedia; 14927; 176 antibodies from 28 providers.
DR DNASU; 11054; -.
DR Ensembl; ENST00000290291.10; ENSP00000290291.6; ENSG00000060491.17. [Q9NZT2-1]
DR GeneID; 11054; -.
DR KEGG; hsa:11054; -.
DR MANE-Select; ENST00000290291.10; ENSP00000290291.6; NM_007346.4; NP_031372.2.
DR UCSC; uc002ydj.4; human. [Q9NZT2-1]
DR CTD; 11054; -.
DR DisGeNET; 11054; -.
DR GeneCards; OGFR; -.
DR HGNC; HGNC:15768; OGFR.
DR HPA; ENSG00000060491; Low tissue specificity.
DR MIM; 606459; gene.
DR neXtProt; NX_Q9NZT2; -.
DR OpenTargets; ENSG00000060491; -.
DR PharmGKB; PA31911; -.
DR VEuPathDB; HostDB:ENSG00000060491; -.
DR eggNOG; ENOG502QVIF; Eukaryota.
DR GeneTree; ENSGT00390000018730; -.
DR HOGENOM; CLU_025735_1_0_1; -.
DR InParanoid; Q9NZT2; -.
DR OMA; TRNWRAM; -.
DR OrthoDB; 1450738at2759; -.
DR PhylomeDB; Q9NZT2; -.
DR TreeFam; TF331377; -.
DR PathwayCommons; Q9NZT2; -.
DR SignaLink; Q9NZT2; -.
DR BioGRID-ORCS; 11054; 105 hits in 1088 CRISPR screens.
DR ChiTaRS; OGFR; human.
DR GeneWiki; OGFr; -.
DR GenomeRNAi; 11054; -.
DR Pharos; Q9NZT2; Tbio.
DR PRO; PR:Q9NZT2; -.
DR Proteomes; UP000005640; Chromosome 20.
DR RNAct; Q9NZT2; protein.
DR Bgee; ENSG00000060491; Expressed in granulocyte and 189 other tissues.
DR ExpressionAtlas; Q9NZT2; baseline and differential.
DR Genevisible; Q9NZT2; HS.
DR GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR GO; GO:0016020; C:membrane; IEA:InterPro.
DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR GO; GO:0140625; F:opioid growth factor receptor activity; IEA:InterPro.
DR GO; GO:0001558; P:regulation of cell growth; NAS:UniProtKB.
DR InterPro; IPR006757; OGF_rcpt.
DR InterPro; IPR006770; OGF_rcpt_rpt.
DR InterPro; IPR039574; OGFr.
DR PANTHER; PTHR14015; PTHR14015; 1.
DR Pfam; PF04680; OGFr_III; 7.
DR Pfam; PF04664; OGFr_N; 1.
PE 1: Evidence at protein level;
KW Acetylation; Alternative splicing; Cytoplasm; Growth regulation; Nucleus;
KW Phosphoprotein; Receptor; Reference proteome; Repeat.
FT CHAIN 1..677
FT /note="Opioid growth factor receptor"
FT /id="PRO_0000058030"
FT REPEAT 517..536
FT /note="1"
FT REPEAT 537..556
FT /note="2"
FT REPEAT 557..576
FT /note="3"
FT REPEAT 577..596
FT /note="4"
FT REPEAT 597..616
FT /note="5"
FT REPEAT 617..636
FT /note="6"
FT REPEAT 637..656
FT /note="7"
FT REGION 1..63
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 295..407
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 421..677
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 517..656
FT /note="7 X 20 AA approximate tandem repeats of [ST]-P-S-E-
FT T-P-G-P-[SR]-P-A-G-P-[AT]-[GR]-D-E-P-A-[EK]"
FT MOTIF 267..283
FT /note="Bipartite nuclear localization signal"
FT /evidence="ECO:0000255"
FT COMPBIAS 1..44
FT /note="Acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 305..319
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 364..393
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 450..465
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 495..509
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 517..531
FT /note="Pro residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT MOD_RES 1
FT /note="N-acetylmethionine"
FT /evidence="ECO:0007744|PubMed:19413330"
FT MOD_RES 299
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:23186163"
FT MOD_RES 315
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:17081983,
FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT MOD_RES 349
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:23186163"
FT MOD_RES 361
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:20068231,
FT ECO:0007744|PubMed:23186163"
FT MOD_RES 378
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:18318008,
FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332,
FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT MOD_RES 382
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:23186163"
FT MOD_RES 403
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:23186163"
FT MOD_RES 420
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:17525332"
FT MOD_RES 484
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:18669648,
FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT MOD_RES 537
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:20068231"
FT MOD_RES 557
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:20068231"
FT MOD_RES 617
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:20068231"
FT MOD_RES 637
FT /note="Phosphoserine"
FT /evidence="ECO:0000250|UniProtKB:Q99PG2"
FT VAR_SEQ 558..577
FT /note="Missing (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:10677613,
FT ECO:0000303|PubMed:15489334"
FT /id="VSP_004060"
FT VARIANT 545
FT /note="R -> S (in dbSNP:rs6122313)"
FT /id="VAR_059706"
FT VARIANT 577
FT /note="S -> T (in dbSNP:rs6122315)"
FT /evidence="ECO:0000269|PubMed:10677613,
FT ECO:0000269|PubMed:11214971, ECO:0000269|Ref.2"
FT /id="VAR_030011"
FT CONFLICT 27..28
FT /note="DG -> EA (in Ref. 2)"
FT /evidence="ECO:0000305"
FT CONFLICT 37..80
FT /note="DAGDEDEESEEPRAARPSSFQSRMTGSRNWRATRDMCRYRHNYP -> GARR
FT ALGVLGQPGGLQMRLPERHGGPQGSLCLMDPCCPLSLALQ (in Ref. 5)"
FT /evidence="ECO:0000305"
FT CONFLICT 50..52
FT /note="AAR -> GPE (in Ref. 2)"
FT /evidence="ECO:0000305"
FT CONFLICT 172
FT /note="E -> A (in Ref. 2)"
FT /evidence="ECO:0000305"
FT CONFLICT 220..221
FT /note="LG -> PC (in Ref. 1; AAF64404/AAF64405)"
FT /evidence="ECO:0000305"
FT CONFLICT 224
FT /note="G -> S (in Ref. 1; AAF64404/AAF64405/AAF64406)"
FT /evidence="ECO:0000305"
FT CONFLICT 240
FT /note="T -> S (in Ref. 2; AAD03745/AAD03737)"
FT /evidence="ECO:0000305"
FT CONFLICT 262
FT /note="R -> G (in Ref. 2; AAD03745/AAD03737)"
FT /evidence="ECO:0000305"
FT CONFLICT 331
FT /note="G -> E (in Ref. 1; AAF64406)"
FT /evidence="ECO:0000305"
FT CONFLICT 398
FT /note="E -> G (in Ref. 1; AAF64406)"
FT /evidence="ECO:0000305"
FT CONFLICT 465
FT /note="A -> T (in Ref. 1; AAF64406)"
FT /evidence="ECO:0000305"
FT CONFLICT 535
FT /note="A -> AKTPSETPGPSPAGPTRDEPA (in Ref. 1; AAF64405)"
FT /evidence="ECO:0000305"
FT CONFLICT 564
FT /note="P -> L (in Ref. 1; AAF64404)"
FT /evidence="ECO:0000305"
FT CONFLICT 576
FT /note="E -> K (in Ref. 1; AAF64406, 2 and 5; BAB15775)"
FT /evidence="ECO:0000305"
FT CONFLICT 577
FT /note="S -> I (in Ref. 1; AAF64406)"
FT /evidence="ECO:0000305"
SQ SEQUENCE 677 AA; 73325 MW; D4DD6AF86291B663 CRC64;
MDDPDCDSTW EEDEEDAEDA EDEDCEDGEA AGARDADAGD EDEESEEPRA ARPSSFQSRM
TGSRNWRATR DMCRYRHNYP DLVERDCNGD TPNLSFYRNE IRFLPNGCFI EDILQNWTDN
YDLLEDNHSY IQWLFPLREP GVNWHAKPLT LREVEVFKSS QEIQERLVRA YELMLGFYGI
RLEDRGTGTV GRAQNYQKRF QNLNWRSHNN LRITRILKSL GELGLEHFQA PLVRFFLEET
LVRRELPGVR QSALDYFMFA VRCRHQRRQL VHFAWEHFRP RCKFVWGPQD KLRRFKPSSL
PHPLEGSRKV EEEGSPGDPD HEASTQGRTC GPEHSKGGGR VDEGPQPRSV EPQDAGPLER
SQGDEAGGHG EDRPEPLSPK ESKKRKLELS RREQPPTEPG PQSASEVEKI ALNLEGCALS
QGSLRTGTQE VGGQDPGEAV QPCRQPLGAR VADKVRKRRK VDEGAGDSAA VASGGAQTLA
LAGSPAPSGH PKAGHSENGV EEDTEGRTGP KEGTPGSPSE TPGPSPAGPA GDEPAESPSE
TPGPRPAGPA GDEPAESPSE TPGPRPAGPA GDEPAESPSE TPGPSPAGPT RDEPAESPSE
TPGPRPAGPA GDEPAESPSE TPGPRPAGPA GDEPAESPSE TPGPSPAGPT RDEPAKAGEA
AELQDAEVES SAKSGKP
